We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Apple, Eli Lilly and Visa
Read MoreHide Full Article
For Immediate Release
Chicago, IL – October 14, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Apple Inc. (AAPL - Free Report) , Eli Lilly and Co. (LLY - Free Report) and Visa Inc. (V - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Stock Reports for Apple, Eli Lilly and Visa
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple Inc., Eli Lilly and Co. and Visa Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
Apple’s shares have outperformed the Zacks Computer - Micro Computers industry over the past year (+7.2% vs. +6.6%). The company is benefiting from strong growth in Services revenues. AAPL now has more than 1 billion paid subscribers across its Services portfolio. Both paid accounts and paid subscriptions grew double digits year over year in third-quarter fiscal 2025.
Apple TV+ viewership soared double-digit year over year. Expanding capabilities of AI Intelligence is noteworthy. Apple expects the September quarter’s (fourth-quarter fiscal 2025) net sales to grow mid to high single digits on a year-over-year basis. AAPL expects the Services year-over-year growth rate to be similar to that of the June quarter.
However, gross margin is expected to be 46-47% in the fourth quarter of fiscal 2025, including a tariff impact of $1.1 billion. Increasing regulatory headwinds and tariffs are a concern for investors.
Shares of Eli Lilly have gained +7.8% over the year-to-date period against the Zacks Large Cap Pharmaceuticals industry’s gain of +8.5%. Demand for the company’s popular GLP-1 drugs, Mounjaro and Zepbound, remains strong, making them the company’s key top-line drivers. Launches of these drugs in new international markets and improved U.S. supply from ramped-up production led to strong sales in the first half of 2025. Lilly’s other new drugs, like Kisunla, Omvoh and Jaypirca, are also contributing to its top-line growth.
However, data from phase III studies on its weight-loss pill, orforglipron, was mixed. Declining sales of Trulicity, rising pricing pressure on some drugs and potential competition in the GLP-1 diabetes/obesity market are some top-line headwinds. Estimates have declined slightly ahead of Q3 results. Lilly has a mixed record of earnings surprises in recent quarters.
Visa’s shares have outperformed the Zacks Financial Transaction Services industry over the year-to-date period (+10.2% vs. -6%). The company’s strong market position is underpinned by consistent volume-driven growth, acquisitions and technological leadership in digital payments. Expansion in cross-border volumes, rising transactions and investments in AI and stablecoin infrastructure enhance its future prospects.
A robust financial position with ample liquidity and shareholder returns further supports long-term growth. However, it faces rising client incentives and expenses, which can weigh on margins. Regulatory pressures and potential legislative changes pose additional risks to its fee structure.
While declining cash volumes align with its digital strategy, regional softness warrants monitoring. Moreover, Visa’s premium valuation suggests limited near-term upside. As such, the stock warrants a cautious stance.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Apple, Eli Lilly and Visa
For Immediate Release
Chicago, IL – October 14, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Apple Inc. (AAPL - Free Report) , Eli Lilly and Co. (LLY - Free Report) and Visa Inc. (V - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Stock Reports for Apple, Eli Lilly and Visa
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple Inc., Eli Lilly and Co. and Visa Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Pre-markets Filling Gaps to Start New Trading Week
Today's Featured Research Reports
Apple’s shares have outperformed the Zacks Computer - Micro Computers industry over the past year (+7.2% vs. +6.6%). The company is benefiting from strong growth in Services revenues. AAPL now has more than 1 billion paid subscribers across its Services portfolio. Both paid accounts and paid subscriptions grew double digits year over year in third-quarter fiscal 2025.
Apple TV+ viewership soared double-digit year over year. Expanding capabilities of AI Intelligence is noteworthy. Apple expects the September quarter’s (fourth-quarter fiscal 2025) net sales to grow mid to high single digits on a year-over-year basis. AAPL expects the Services year-over-year growth rate to be similar to that of the June quarter.
However, gross margin is expected to be 46-47% in the fourth quarter of fiscal 2025, including a tariff impact of $1.1 billion. Increasing regulatory headwinds and tariffs are a concern for investors.
(You can read the full research report on Apple here >>>)
Shares of Eli Lilly have gained +7.8% over the year-to-date period against the Zacks Large Cap Pharmaceuticals industry’s gain of +8.5%. Demand for the company’s popular GLP-1 drugs, Mounjaro and Zepbound, remains strong, making them the company’s key top-line drivers. Launches of these drugs in new international markets and improved U.S. supply from ramped-up production led to strong sales in the first half of 2025. Lilly’s other new drugs, like Kisunla, Omvoh and Jaypirca, are also contributing to its top-line growth.
However, data from phase III studies on its weight-loss pill, orforglipron, was mixed. Declining sales of Trulicity, rising pricing pressure on some drugs and potential competition in the GLP-1 diabetes/obesity market are some top-line headwinds. Estimates have declined slightly ahead of Q3 results. Lilly has a mixed record of earnings surprises in recent quarters.
(You can read the full research report on Eli Lilly here >>>)
Visa’s shares have outperformed the Zacks Financial Transaction Services industry over the year-to-date period (+10.2% vs. -6%). The company’s strong market position is underpinned by consistent volume-driven growth, acquisitions and technological leadership in digital payments. Expansion in cross-border volumes, rising transactions and investments in AI and stablecoin infrastructure enhance its future prospects.
A robust financial position with ample liquidity and shareholder returns further supports long-term growth. However, it faces rising client incentives and expenses, which can weigh on margins. Regulatory pressures and potential legislative changes pose additional risks to its fee structure.
While declining cash volumes align with its digital strategy, regional softness warrants monitoring. Moreover, Visa’s premium valuation suggests limited near-term upside. As such, the stock warrants a cautious stance.
(You can read the full research report on Visa here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.